Solvonis Therapeutics (SVNS LN)

Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, with an initial focus on addiction and mental health. The company is advancing a pipeline of repurposed and novel compounds, including lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Headquartered in London, United Kingdom, the company was founded in 2017.